Joy Bauch

2.7k total citations
20 papers, 751 citations indexed

About

Joy Bauch is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Joy Bauch has authored 20 papers receiving a total of 751 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Immunology. Recurrent topics in Joy Bauch's work include Protein Kinase Regulation and GTPase Signaling (5 papers), Cancer therapeutics and mechanisms (3 papers) and HER2/EGFR in Cancer Research (3 papers). Joy Bauch is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (5 papers), Cancer therapeutics and mechanisms (3 papers) and HER2/EGFR in Cancer Research (3 papers). Joy Bauch collaborates with scholars based in United States, United Kingdom and Germany. Joy Bauch's co-authors include Saul H. Rosenberg, Kennan C. Marsh, Christin Tse, Steven W. Elmore, Stephen W. Fesik, Xiufen Yang, Jessica Adickes, Xilu Wang, Marion Refici and David J. Frost and has published in prestigious journals such as Blood, Clinical Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Joy Bauch

20 papers receiving 733 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joy Bauch United States 12 456 182 172 72 58 20 751
Bertrand Leblond France 17 665 1.5× 142 0.8× 259 1.5× 101 1.4× 35 0.6× 29 1.2k
Danny Tam United States 14 449 1.0× 144 0.8× 119 0.7× 77 1.1× 135 2.3× 25 870
Kenichi Mori Japan 16 500 1.1× 114 0.6× 90 0.5× 66 0.9× 47 0.8× 51 982
Shinichi Imamura Japan 19 380 0.8× 142 0.8× 285 1.7× 52 0.7× 67 1.2× 30 788
Claudia Rosenbaum Germany 16 445 1.0× 90 0.5× 276 1.6× 48 0.7× 18 0.3× 26 836
Christina Esdar Germany 15 460 1.0× 182 1.0× 86 0.5× 58 0.8× 40 0.7× 38 698
Paolo Cappella Italy 15 561 1.2× 275 1.5× 80 0.5× 33 0.5× 39 0.7× 28 840
Kathleen M. Gillooly United States 14 263 0.6× 166 0.9× 145 0.8× 263 3.7× 51 0.9× 17 778
Nilla Avanzi Italy 15 459 1.0× 263 1.4× 120 0.7× 59 0.8× 75 1.3× 27 778
Gengjie Yang United States 13 291 0.6× 289 1.6× 87 0.5× 182 2.5× 50 0.9× 21 814

Countries citing papers authored by Joy Bauch

Since Specialization
Citations

This map shows the geographic impact of Joy Bauch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joy Bauch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joy Bauch more than expected).

Fields of papers citing papers by Joy Bauch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joy Bauch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joy Bauch. The network helps show where Joy Bauch may publish in the future.

Co-authorship network of co-authors of Joy Bauch

This figure shows the co-authorship network connecting the top 25 collaborators of Joy Bauch. A scholar is included among the top collaborators of Joy Bauch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joy Bauch. Joy Bauch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Silver, Mitchell, Brenda Phillips, Eduardo Beck, et al.. (2012). Evaluation of the Oral Antimitotic Agent (ABT-751) in Dogs with Lymphoma. Journal of Veterinary Internal Medicine. 26(2). 349–354. 4 indexed citations
2.
Thaete, Larry G., et al.. (2012). Endothelin receptor antagonist has limited access to the fetal compartment during chronic maternal administration late in pregnancy. Life Sciences. 91(13-14). 583–586. 13 indexed citations
3.
Segreti, Jason A., Kennan C. Marsh, Joy Bauch, et al.. (2010). Tumour‐selective antivascular effects of the novel anti‐mitotic compound A‐318315: Anin vivorat regional haemodynamic study. Clinical and Experimental Pharmacology and Physiology. 37(5-6). 636–640. 3 indexed citations
4.
Milicic, Ivan, Joy Bauch, Bruce W. Surber, et al.. (2009). Use of the H3receptor antagonist radioligand [3H]‐A‐349821 to revealin vivoreceptor occupancy of cognition enhancing H3receptor antagonists. British Journal of Pharmacology. 157(1). 139–149. 16 indexed citations
5.
Muscal, Jodi A., Patrick A. Thompson, Vincent L. Giranda, et al.. (2009). Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemotherapy and Pharmacology. 65(3). 419–425. 28 indexed citations
6.
Ackler, Scott, Xiao Yu, Michael J. Mitten, et al.. (2008). ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics. 7(10). 3265–3274. 64 indexed citations
7.
Park, Cheol‐Min, Milan Bruncko, Jessica Adickes, et al.. (2008). Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins. Journal of Medicinal Chemistry. 51(21). 6902–6915. 228 indexed citations
8.
Shoemaker, Alex R., Michael J. Mitten, Jessica Adickes, et al.. (2008). Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models. Clinical Cancer Research. 14(11). 3268–3277. 155 indexed citations
9.
Chen, Yung‐Wu, Morey L. Smith, Michael P. Sheets, et al.. (2007). Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression. Journal of Cardiovascular Pharmacology. 49(4). 228–235. 55 indexed citations
10.
Cho, Steve Y., Elizabeth Fox, Cynthia Lester McCully, et al.. (2006). Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates. Cancer Chemotherapy and Pharmacology. 60(4). 563–567. 5 indexed citations
11.
Elmore, Steven W., Joy Bauch, Ryan M. Fryer, et al.. (2006). Bcl-2 Family Protein Inhibitors Induce a Unique Thrombocytopenia In Vivo.. Blood. 108(11). 4236–4236. 2 indexed citations
12.
Shoemaker, Alex R., Michael J. Mitten, Jessica Adickes, et al.. (2006). The Bcl-2 Family Inhibitor ABT-263 Shows Significant but Reversible Thrombocytopenia in Mice.. Blood. 108(11). 1107–1107. 5 indexed citations
13.
Ferguson, Debra C., Luis E. Rodrı́guez, Joann P. Palma, et al.. (2005). Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models. Clinical Cancer Research. 11(8). 3045–3054. 20 indexed citations
14.
Lin, Nan‐Horng, Qun Li, Rodger F. Henry, et al.. (2004). Synthesis of 1H-pyridin-2-one derivatives as potent and selective farnesyltransferase inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(18). 4603–4606. 10 indexed citations
15.
Wang, Le, Gary T. Wang, Xilu Wang, et al.. (2004). Design, Synthesis, and Biological Activity of 4-[(4-Cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as Potent and Selective Farnesyltransferase Inhibitors. Journal of Medicinal Chemistry. 47(3). 612–626. 29 indexed citations
16.
Hasvold, Lisa, Weibo Wang, Stephen L. Gwaltney, et al.. (2003). Pyridone-Containing farnesyltransferase inhibitors: synthesis and biological evaluation. Bioorganic & Medicinal Chemistry Letters. 13(22). 4001–4005. 64 indexed citations
17.
Tong, Yunsong, Nan‐Horng Lin, Le Wang, et al.. (2003). Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability. Bioorganic & Medicinal Chemistry Letters. 13(9). 1571–1574. 18 indexed citations
18.
Wang, Shen, Stephen A. Fakhoury, Kenneth J. Henry, et al.. (1999). Potent inhibitors of protein farnesyltransferase: Heteroarenes as cysteine replacements. Bioorganic & Medicinal Chemistry Letters. 9(5). 703–708. 7 indexed citations
19.
Chen, Yung‐Wu, Morey L. Smith, Michael P. Sheets, et al.. (1999). Ex VivoAssessment of Immunosuppression in Undiluted Whole Blood from Pigs Dosed with Tacrolimus (FK506). Clinical Immunology. 90(1). 133–140. 3 indexed citations
20.
Kirschbaum, Clemens, Lea Jabaaij, Angelika Buske-Kirschbaum, et al.. (1992). Conditioning of drug‐induced immunomodulation in human volunteers: A European Collaborative Study. British Journal of Clinical Psychology. 31(4). 459–472. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bertrand Leblond Breakdown of academic impact, for papers by Danny Tam Breakdown of academic impact, for papers by Kenichi Mori Breakdown of academic impact, for papers by Shinichi Imamura Breakdown of academic impact, for papers by Claudia Rosenbaum Breakdown of academic impact, for papers by Christina Esdar Breakdown of academic impact, for papers by Paolo Cappella Breakdown of academic impact, for papers by Kathleen M. Gillooly Breakdown of academic impact, for papers by Nilla Avanzi Breakdown of academic impact, for papers by Gengjie Yang
Rankless by CCL
2026